Day 1, Wednesday 21 November 2018				
	Parallel Session 1: Healthcare-associated infections Time: 11:00-12:40 Moderator: Ágnes Hajdu	Parallel Session 2: Emerging and vector-borne diseases (1) Time: 11:00-12:40 Moderator: Pawel Stefanoff	Parallel Session 3: Food- and waterborne diseases and zoonoses (1): microbiology and whole genome sequencing Time: 11:00-12:40 Moderator: Androulla Efstratiou	
	 1.1. Validation of an electronic nationwide surveillance system for periprosthetic joint infections following primary total knee replacement in Denmark, Ingmarie Johanson 1.2. Estimating inappropriate antibiotic prescribing in secondary care in England: analysis of the 2016 healthcare-associated infection and antimicrobial usage point prevalence survey, Rachel Freeman 1.3. Occupational exposure to percutaneous injuries and prevalence of HBV, HCV and HIV among hospital staff in Poland: a multicenter study, Maria Ganczak 1.4. Epidemiology and impact of norovirus outbreaks in Norwegian healthcare institutions, 2006-2018, Laura Espenhain 1.5. Factors associated with Methicillin-Resistant Staphylococcus aureus (MRSA) acquisition rates of wards in a Singapore tertiary hospital: An electronic medical records study, Zaw Myo Tun 	 2.1. Lyme Borreliosis in Bavaria, Germany: Results from 5 Years of Epidemiological Surveillance, Merle M. Böhmer 2.2. Occupational swine exposure associated with seropositivity for Ascaris suum in veterinarians in Austria, 2017/2018, Karin Taus 2.3. Evaluation of the seasonal human surveillance system for neuroinvasive West Nile virus infections in France: a surveillance system that does not meet its objective, Lauriane Ramalli 2.4. Circulation of non-polio enterovirus and human parechovirus types in the EU/EEA Member States, 2015-2017, Laura Bubba 2.5. Syndromic and digital surveillance of tick-borne encephalitis in Sweden, 2010-2017, Leah J Martin 	 3.1. The neglected infection: Trends in Giardia cases and associated exposures after the introduction of molecular testing, 2000-2017, northeast England, Alison Waldram 3.2. Combining whole genome sequencing and epidemiological investigation to link intermittent Salmonella Agona cases to long term environmental contamination at two Yorkshire pubs, Lara A. Utsi 3.3. A national Salmonella Typhimurium outbreak investigation in Great Britain identifies the whole genome sequence outbreak strain in multiple animal species in different regions, Paul Crook 3.4. An outbreak of Listeria monocytogenes CT1234 in Austria linked by Trace-Back and Whole-genome Sequencing, 2015 – 2018, Sabine Maritschnik 3.5. Impact of whole genome sequencing on foodborne outbreak detection and response in Canada, Ashley Kerr 	
	Parallel Session 4: Food- and waterborne diseases and zoonoses (2): epidemiology and surveillance 1 Time: 14:30-15:30 Moderator: Daniel Thomas 4.1. Tularemia incidence and association with rodent population dynamics, Norway, 2005-2017, Lamprini Veneti 4.2. The prevalence and risk factors for human echinococcosis—Alaiski District, Kyrgyz republic, 2016, Aizat Arunova 4.3. Shigellosis in Ireland: re-emergence in a new risk group, Patricia Garvey	Parallel Session 5: International health and migration Time: 14:30-15:30 Moderator: Ines Steffens 5.1. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in the Netherlands, Irene Veldhuijzen 5.2. A qualitative-quantitative study helped identify the most relevant issues with vaccination and improve communication in an asylum-seeker camp in Poland, Savina Stoitsova 5.3. High Acceptability and Satisfaction among Health Facility Informants using Mobile Digital Surveillance Outbreak Response Management and Analysis System (SORMAS) after Follow-up in Kano, Nigeria 2018, Daniel Tom-Aba	Parallel Session 6: Vaccine-preventable diseases (1): epidemiology and surveillance Time: 14:30-15:30 Moderator: Peter Kreidl 6.1. Prevalence of and factors associated with pneumococcal carriage in Norwegian children, four years after introduction of the 13-valent Pneumococcal Conjugate Vaccine, Astrid Lovlie 6.2. The severity and clinical manifestation of invasive meningococcal serogroup W disease in comparison to other serogroups in the Netherlands, Anna D. Loenenbach 6.3. Striking differences in reported pertussis incidence between Norway and Sweden not confirmed in seroepidemiology, 2012-13, Sharon Kühlmann-Berenzon	



Day 2: Thursday, 22 November				
Parallel Session 7: Cholera Time: 11:00-12:40 Moderator: Oliver Morgan	Parallel Session 8: Food- and water-borne diseases and zoonoses (3): outbreaks Time: 11:00-12:40 Moderator: Anders Wallensten	Parallel Session 9: Vaccine-preventable diseases (2): vaccine effectiveness Time: 11:00-12:40 Moderator: TBC		
7.1. The geographical spread of the cholera epidemic in the Democratic Republic of the Congo. An analysis of national syndromic and laboratory surveillance data, 2008-17, David Hendrickx 7.2. High case fatality during cholera outbreaks in nonendemic provinces, Democratic Republic of the Congo (DRC), 2008-17, Brecht Ingelbeen 7.3. Preparedness of primary healthcare facilities to respond to a cholera outbreak in Kinshasa, Democratic Republic of the Congo, 2018, Patricia Ndumbi 7.4. High cholera vaccination coverage following emergency campaign in Haiti: results from a spatial cluster survey, Ashley Sharp 7.5. Late breaker: Cholera Outbreak Response in a Complex Emergency: The Importance of Oral Cholera Vaccine in Borno State, North-eastern Nigeria, January, 2018, Kumshida Balami	 8.1. Rapid investigation of hepatitis A outbreak led to recall of Iranian dates, Denmark 2018, Luise Müller 8.2. Outbreak of Clostridium perfringens associated with consumption of roasted meat and gravy at a buffet on Mothering Sunday 2018, Simon Packer 8.3. An outbreak of campylobacteriosis at a rural hotel in England: the ongoing risk of outbreaks due to consumption of chicken liver dishes, Adrian Wensley 8.4. Human brucellosis outbreak, March to September 2017, South Morocco, Hind Majidi 8.5. Late breaker: From local to national to international: Salmonella enteritidis outbreak in a Chinese restAurant linked via Whole Genome Sequencing (WGS) to European outbreak, Natalie Wright 	9.1. Effectiveness of one dose of acellular pertussis vaccine in hospitalised infants in six EU/EEA countries: preliminary results of the ECDC PERTINENT project, 2016-2018, Lore Merdrignac 9.2. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in older adults by high risk conditions type: Results of SpIDnet/I-MOVE+ multicentre study, Camelia Savulescu 9.3. Invasive pneumococcal disease in Tuscany region, Italy: integrating multiple data sources to estimate underreporting and underdiagnosis, Filippo Quattrone 9.4. Invasive pneumococcal disease caused by serotypes 3 and 19A in older adults of 10 European countries after six years of childhood PCV10/13 vaccination, Germaine Hanquet 9.5. Late breaker: Vaccination policy towards the tail of the diphtheria outbreak among Rohingya population in Cox's Bazar, Bangladesh – challenges and way forward, Katri Jalava		
Parallel Session 10: Vaccine-preventable diseases (3): developments and methods	Parallel Session 11: HIV, sexually transmitted infections and viral hepatitis (1): epidemiology and surveillance	Parallel Session 12: Food- and waterborne diseases and zoonoses (4): epidemiology and surveillance 2		
Time: 14:30-15:30	Time: 14:30-15:30	Time: 14:30-15:30		
Moderator: TBC	Moderator: Andrew Amato	Moderator: Steen Ethelberg		
10.1. Evaluating vaccination programmes for policy decisions by using population-based registers—example of reductions in the total disease burden due to infant pneumococcal conjugate vaccination in Finland, Arto A. Palmu 10.2. Development of recombinant human anti-diphtheria toxin neutralizing antibody for diphtheria therapy, Esther Wenzel 10.3. Controlling the developing Meningitis W outbreak in the Netherlands; insights from model-based infectious disease data analysis, Albert Jan van Hoek	11.1. Concurrent outbreaks of extensively-resistant Shigella sonnei and Shigella flexneri in men who have sex with men, Melbourne Australia, Deborah Williamson 11.2. Risk behaviours of homeless people who inject drugs during an outbreak of hepatitis C, Northern Ireland, 2016-2017, Anna Maisa 11.3. Hidden in plain sight, MSM engaging in 'chemsex' as an emerging risk group for STI/HIV, Ymke J Evers	12.1. Effects of reduced typing coverage for routine Salmonella surveillance in France, Mikhail Churakov 12.2. Decreasing seroprevalence of Toxoplasma infection amongst pregnant women in France: is it time to change the screening policy?, Eve Robinson 12.3. "Sickenin' in the rain" - increased risk of gastrointestinal and respiratory infections after urban pluvial flooding, Annemieke Mulder		
Parallel Session 13: Antimicrobial resistance	Parallel Session 14: Tuberculosis	Parallel Session 15: Vaccine- preventable diseases (4): vaccine uptake and coverage		
Time: 17:00-18:40 Moderator: Jan Walter	Time: 17:00-18:40 Moderator: Loredana Ingrosso	Time: 17:00-18:40 Moderator: Alma Tostmann		
13.1. Antimicrobial resistance in Aspergillus fumigatus isolated February to September 2017 from clinical specimens in Lyon, France, Rolf Kramer	14.1. Implementation of WGS tuberculosis cluster surveillance; rapid identification and robust public health management in the East Midlands, 2017-2018, Hikaru Bolt	15.1. Direct and indirect effects of the recommendation for routine Rotavirus-vaccination on notified rotavirus cases and vaccine uptake in infants in Germany 2013-2017, Adine Marquis		

13.1. Antimicrobial resistance in Aspergillus fu			
isolated February to September 2017 from clin			
specimens in Lyon, France, Rolf Kramer			

- 13.2. OXA-48-producing Enterobacteriales detected in Irish seawater, 2017, Bláthnaid Mahon
- 13.3. National surveillance of methicillin-resistant Staphylococcus aureus bacteraemia following the implementation of Whole-Genome Sequencing in England, April-December 2017, Laura Bubba
- 13.4. Burden of infections caused by antibiotic-resistant Area in 2015 using disability-adjusted life years, Alessandro implications for TB control, Angela Cannas
- East Midlands, 2017-2018, Hikaru Bolt
- 14.2. Level of none-adherence to anti-tuberculosis treatment and risk factors associated with it among 2014-2015 cohorts of pulmonary tuberculosis adult patients, Bishkek City, Kyrgyz Republic, Ekaterina Maliukova
- 14.3. Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe, Basel Karo
- 14.4. Implementation of Whole-genome sequencing of bacteria in the European Union and the European Economic | Mycobacterium tuberculosis in a referral TB hospital in Rome:
 - 14.5. Risk factors for delay in initiation of treatment for pulmonary TB: a time-to-event analysis using linked TB surveillance and clinical case review data in the South East of England, 2011-2015, David James Roberts

- uptake in infants in Germany 2013-2017, Adine Marquis
- 15.2. Extension of the mandatory vaccination program, perception of the French population, Pauline Mathieu
- 15.3. Is mandatory vaccination influencing maternal decision to vaccinate children in Slovenia? April-May 2016, Mario Fafangel
- 15.4. Vaccine hesitancy: low uptake of influenza vaccine among Polish population in Lothian, Scotland, Lorna Willocks
- 15.5. Impact of Italy's law 119/2017 regarding mandatory vaccination seven months since it was enforced: experience in the Apulia region, **Domenico Martinelli**



Day 3: Friday, 23 November

Day 3: Friday, 23 November			
and viral hepatitis (2): surveillance, screening & intervention Time: 11:00-12:40 Moderator: Helena de Carvalho Gomes	Parallel Session 17: Influenza and other respiratory viruses (1): epidemiology and surveillance Time: 11:00-12:40 Moderator: Julien Beauté	Time: 11:00-12:40 Moderator: Alain Moren	
16.1. Does the German screening policy for Chlamydia trachomatis target those most at risk? – Results from the German health examination survey (DEGS) 2008-2011, Martyna Gassowski 16.2. Oropharyngeal testing and positivity at the STI clinic in the past 5 years; testing more and finding even more, Geneviève AFS van Liere 16.3. Impact of nurse led enhanced monitoring, management and contact tracing intervention for chronic hepatitis B in England, 2015-2017, Kazim Beebeejaun 16.4. Effectiveness of three alternative hepatitis B revaccination series (Fendrix®, Twinrix® and HBVaxPro-40®) in healthy non-responders; an open-label randomised controlled multicentre trial, Stijn Raven 16.5. High positivity of sexually transmitted infections in men who have sex with men in the times of HIV pre-exposure prophylaxis (PrEP) - results of a cross-sectional multicentre study in Germany, 2018, Gyde Steffen	17.1. Whole genome analysis of influenza A(H3) viruses detected between 2016-2018 in the scope of EuroEVA/I-MOVE vaccine effectiveness study, Pedro Pechirra 17.2. Predicting peak influenza activity in primary and secondary care in Scotland – is the Moving Epidemic Method the way forward?, Diogo F P Marques 17.3. Development of a system of automated analysis and reporting for pandemic influenza severity assessment in England, Ashley Sharp 17.4. Previous exposure to natural infection matters - The effect of influenza A infection in 2016/17 on influenza A and B infection in 2017/18 in the Finnish elderly, Ulrike Baum 17.5. Factors associated with admission to intensive care units (ICUs) and/or death among severe hospitalized confirmed influenza cases, Spain, 2010 – 2018, Concepción Delgado-Sanz	18.1. Monitoring the dynamics of public perceptions of meningococcal disease and vaccination: The case of an ongoing outbreak in the Netherlands, Marion de Vries 18.2. Detection of two seropositive infections with antibodies to zoonotic Borna disease virus-1 (BoDV-1) in a retrospective serosurvey among 424 veterinarians working in an endemic area in Germany, Hendrik Wilking 18.3. Outbreak of Legionella non-pneumophila subspecies associated with gardening and usage of commercial bagged soil in Sweden, 2018, Emma Löf 18.4. Second epidemic wave of a large measles outbreak in Italy, 2018, amid vaccination policy changes, Xanthi Andrianou 18.5. Exploiting publically available microbial genomic data for detecting linked cases in global outbreaks, Anaïs Painset	
Parallel Session 19: Vaccine- preventable diseases (5): preparedness Time: 14:30-15:30 Moderator: Katharina Alpers 19.1. Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe,	Parallel Session 20: Influenza and other respiratory viruses (2): vaccination Time: 14:30-15:30 Moderator: Richard Pebody 20.1. 2017–18 Vaccine effectiveness against influenza A(H ₃ N ₂) and lineage mismatched influenza B in older adults: Results from	Parallel Session 21: Emerging and vector-borne diseases (2) Time: 14:30-15:30 Moderator: Sooria Balasegaram 21.1. Whole genome sequence analysis reveals a novel cluster of strains with a unique amino acid substitution pattern, responsible	
Laurence Torcel-Pagnon 19.2. Getting ahead of the wave: informing public health action through mapping to identify populations at high risk of measles introduction and transmission, Mary Cronin 19.3. ADVANCE system testing: vaccine benefit studies by using multi-country electronic health data - An example on pertussis vaccination, Myint Tin Tin Htar	the I-MOVE+ hospital network, Angela MC Rose 20.2. High live-attenuated influenza vaccine effectiveness against influenza B in two-year-olds, 2017/18, Finland, Ulrike Baum 20.3. Cost-effectiveness analysis of seasonal influenza vaccination strategies targeting children and/or the elderly in 6 European countries and regions, Frank Sandmann	for the recent Italian-2017 and Pakistani-2016 Chikungunya virus outbreaks, Erika Lindh 21.2. The epidemic risks from new mosquito borne diseases in Greece in economic terms, Antonios Kolimenakis 21.3. Zika virus in Pregnancy: a retrospective case control study, French Polynesia, 2013-2016, Lorenzo Subissi	

